NASDAQ · OCGN
Ocugen, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for OCGN: Nov 04, 2026
Ocugen, Inc. Common Stock is expected to report earnings on 11/04/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.06. The reported EPS for the same quarter last year was $-0.07.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.06 | $-0.04 | $-0.07 | 3 |
| Dec 2026 | $-0.06 | $-0.04 | $-0.07 | 3 |
| Mar 2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Jun 2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · Zacks · The Motley Fool- RTTNews · Oct 14, 8:14 AM EDTOcugen Expands OCU400 Gene Therapy Reach With $255 Mln Milestone Deal(RTTNews) – Ocugen, Inc. (OCGN), a biotechnology company developing gene therapies for blindness diseases, announced that it has entered into an exclusive licensing agreement with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding for OCU400, an investig
- RTTNews · Oct 14, 7:49 AM EDTOcugen Licenses OCU400 Gene Therapy To Roots Pharmaceutical For MENA Region(RTTNews) – Ocugen, Inc. (OCGN), a biotechnology company developing gene therapies for blindness diseases, announced on Wednesday that it has entered into an exclusive licensing agreement with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding for OCU400
- RTTNews · Sep 25, 10:45 AM EDTOcugen Gains Bahamas Approval Pathway For OCU400 Retinitis Pigmentosa Therapy(RTTNews) – Ocugen Inc. (OCGN), a biotechnology company developing gene therapies for blindness diseases, announced that its investigational modifier gene therapy OCU400 has received provisional approval and priority designation from the Longevity and Regenerative Therapies Board
- MarketBeat · Sep 16, 12:02 AM EDTOcugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline AdvancesOcugen (NASDAQ:OCGN) is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri said during a company discussion. The com
- Zacks · Sep 2, 10:52 AM EDTOCGN Advances Gene Therapy OCU410 In Phase III for Geographic AtrophyOcugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.
- MarketBeat · Aug 15, 9:01 PM EDTOcugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key ReadoutsOcugen (NASDAQ:OCGN) is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in retinitis pigmentosa, Stargardt disease and geographic atrophy, Chairman, CEO and
- The Motley Fool · Aug 13, 2:14 PM EDTOcugen (OCGN) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 7, 1:18 PM EDTOcugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock FallsOCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.
- MarketBeat · Aug 7, 2:04 AM EDTOcugen Q2 Earnings Call HighlightsOcugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program. Chairman, Chief Executive Officer and Co-Founder
- Zacks · Aug 6, 9:50 AM EDTOcugen (OCGN) Reports Q2 Loss, Beats Revenue EstimatesOcugen (OCGN) delivered earnings and revenue surprises of -40.00% and +6.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 30, 6:00 PM EDTIllumina (ILMN) Tops Q2 Earnings and Revenue EstimatesIllumina (ILMN) delivered earnings and revenue surprises of +6.50% and +3.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 30, 5:25 AM EDTOcugen Wins FDA RMAT Designation For OCU410 In Dry AMD- Related Geographic Atrophy(RTTNews) – Ocugen, Inc. (OCGN), a biotechnology company developing gene therapies for blinding diseases, announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) status to OCU410 for the treatment of Geographic atrophy in secondary to dry age-related
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Ocugen, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.